The effect of DHEA on the activation of the xenosensors PPARα, PXR and CAR, and the consequent potential for adverse drug/toxicant interactions should be considered in humans treated with this nutriceutical agent.
INTRODUCTION
Dehydroepiandrosterone (DHEA), the major secretory product of the adrenal cortex, is the most abundant steroid in humans and has multifunctional properties: it is a precursor of sex steroid hormones and a peroxisome proliferator at pharmacological dosages (Wu et al., 1989) . DHEA is derived from cholesterol via a series of steps catalyzed by cytochrome P450 (CYP) enzymes (Miller, 2002) . Physiological concentrations of DHEA and its sulfate derivative in human plasma are in the micromolar range and increase significantly in individuals consuming high amounts of DHEA (Legrain et al., 2000) . It is secreted primarily as 3β-sulfate conjugate (DHEA:DHEA-S ratio 1:250 or 1:500 in plasma) which is taken up by target tissues and hydrolyzed by sulfatases back to DHEA (Labrie et al., 1997; Webb et al., 2006) . DHEA is further metabolized to androgens and estrogens in testis and ovary (Labrie et al., 2005) , or to hydroxylated metabolites in the liver. DHEA is hydroxylated to 7α/β-hydroxy-, or 16α-hydroxy-metabolites by microsomal CYP enzymes (Miller et al., 2004; Chalbot and Morfin, 2005) . Some of the hydroxylated metabolites are further oxidized to oxoderivatives (Fitzpatrick et al., 2001; Miller et al., 2004) .
DHEA has been suggested to display beneficial effects in humans including reduced serum cholesterol, lower incidence of cardiovascular disease, weight loss, and improved control of plasma glucose in patients with diabetes (Kawano et al., 2003; Villareal and Holloszy, 2004) . DHEA also protects against chemically-induced carcinogenesis (Lubet et al. 1998 ) and certain immune deficiencies (Henderson et al., 1992) in animal models.
Furthermore, DHEA has been documented to be a neuroactive steroid displaying neuroprotective and memory-enchancing effects (Baulieu et al., 2000) . In addition to these beneficial effects, chronic administration of DHEA at high doses to rodents stimulates several pathophysiological changes such as hepatomegaly and hepatocellular carcinoma (Rao et al., 1992) .
This article has not been copyedited and formatted. The final version may differ from this version. DMD Fast Forward. Published on June 25, 2007 as DOI: 10.1124 at ASPET Journals on July 6, 2017 dmd.aspetjournals.org Downloaded from DHEA administration to rats at supraphysiological doses has been reported to increase the expression of several genes including CYP4As, CYP3As, NADPH:cytochrome c oxidoreductase, catalase, or fatty acyl-CoA oxidase (Wu et al., 1989; Prough et al., 1994; Webb et al., 1996; Gu et al., 2003) . Several drugs including clofibrate and nafenopin also induce CYP4A transcription by activation of peroxisome proliferator activated receptor α (PPARα). Although induction of CYP4A expression by DHEA requires activation of PPARα, DHEA does not appear to be a ligand for PPARα (Prough et al., 1994; Peters et al., 1996) .
Receptor activation is possibly the result of an effect of phosphorylation status of PPARα (Webb et al., 2006) . Furthermore, studies with primary cultures of rat hepatocytes revealed that several oxidative metabolites of DHEA produced in liver are also able to activate CYP4A message and protein levels (Webb et al., 1996) . 7-Oxidized metabolites (7-hydroxy-DHEA and 7-oxo-DHEA) do not serve as ligands for PPARα, but they are presumed to activate PPARα in the way similar to the parent compound. Treatments of rats with pharmacological doses of DHEA result in alteration in expression of other genes responsive to peroxisome proliferators, including fatty acyl-CoA oxidase or malic enzyme. DHEA exerts regulatory effects not only on peroxisome proliferation associated genes, but also on CYP3A23 gene in rats (Singleton et al., 1999) . This observation was due to DHEA activation of the pregnane X receptor (PXR), a member of the nuclear receptor superfamily known to mediate induction of CYP3A expression (Jones et al., 2000; Ripp et al., 2002) . Negative regulation of CYP2C11 expression by peroxisome proliferators has also been demonstrated in rats, although with DHEA, PPARα coexpression does not seem to be required for negative regulation (Ripp et al., 2003) . The main goal of the present study was to examine the CYP inducing capacity of DHEA and of two of its metabolites (7α-hydroxy-DHEA and 7-oxo-DHEA) in primary culture of human hepatocytes. In addition to PXR action, we provided evidence for a role of CAR (constitutive androstane receptor) in the induction of certain CYP genes by DHEA. 
Materials and Methods
Chemicals. 5-Androsten-3β-ol-17-one (DHEA), 5-androsten-3β,7α-diol-17-one (7α-hydroxy-DHEA) and 5-androsten-3β-ol-7,17-dione (7-oxo-DHEA) were purchased from Steraloids, Inc. (Newport, RI). Dexamethasone, SR-12813 (tetra-ethyl 2-(3,5-di-tert-butyl-4-hydroxyphenyl)ethenyl-1,1-bisphosphonate), 5α-androstan-3β-ol (androstanol), and dimethylsulfoxide were the products of Sigma Chemie GmbH (Deisenhofen, Germany).
3,3',5,5'-Tetrachloro-1,4-bis(pyridyloxy)benzene (TCPOBOP) was purchased from Bayer AG (Leverkusen, Germany of Basel (Basel, Switzerland). Primary hepatocytes of control (CAR+/+) and CAR knockout (CAR-/-) mice were prepared by a two step collagenase method (Bayliss and Skett, 1996) .
Liver cells were plated at a density of 3x10 5 cells/well on 12-well plates coated with collagen and maintained in medium described by Ferrini et al. (1998) . Hepatocytes were exposed to TCPOBOP (10 µM), DHEA (25 µM) or vehicle (DMSO 0.1%) for 24 hr.
CYP enzyme assays. Microsomal fraction from cultured human hepatocytes was prepared by differential centrifugation (van der Hoeven and Coon, 1974) . Protein content of microsomes was determined by the method of Lowry et al. (1951) , with bovine serum albumin as the standard. Published methods were followed to determine selective CYP enzyme activities: mephenytoin N-demethylation for CYP2B6 (Heyn et al., 1996) , tolbutamide 4-hydroxylation for CYP2C9 (Miners and Birkett, 1996) , mephenytoin 4'-hydroxylation for CYP2C19 (Srivastava et al., 1991) Eighteen hr after transfection, hepatocytes were exposed to DHEA (50 µM) or CITCO (100 nM) for 4 hr, then washed twice with phosphate-buffered saline (PBS) solution and fixed in 4% (w/v) paraformaldehyde. Cells were stained with DAPI (4'-6-diamidino-2-phenylindole) and then washed again with PBS. The coverslips were transferred to microscope slides and visualized in Moviol mounting medium. The intracellular localization of CAR-GFP fusion protein was determined by fluorescence microscopy using a Leica DM5000B microscope (Leica Microsystems,Wetzlar GmbH, Wetzlar, Germany) and AnalySIS Pro software (Soft Imaging System GmbH, Münster, Germany).
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Results
Previous work has clearly demonstrated CYP inducing effect of DHEA in rats (Prough et al., 1994; Singleton et al., 1999; Gu et al., 2003) . Work by Peters et al. (1996) and Ripp et al. (2002) has shown that DHEA acts on CYP4As and CYP3A23 at the transcriptional level by PPARα-and PXR-mediated event, respectively. Oxidative metabolites of DHEA have also been reported to activate PPARα and consequently to induce CYP4A in rat hepatocytes (Webb et al., 2006) . The present study further characterizes the actions of DHEA and of some of its metabolites, 7α-hydroxy-DHEA and 7-oxo-DHEA (Miller et al., 2004; Chalbot and Morfin, 2005) , to induce CYPs in adult human hepatocytes. We also attempted to elucidate the role of nuclear receptors, PXR and CAR in the induction of CYPs by DHEA.
CYP induction by DHEA in human hepatocytes. It was ascertained in preliminary experiments that 50 µM of DHEA was required for maximal induction of CYP activities in cultured human hepatocytes (data not shown). In subsequent studies, this concentration of DHEA, 7α-hydroxy-DHEA or 7-oxo-DHEA was used for treatment of hepatocytes. The synthetic glucocorticoid, dexamethasone was used as a reference compound at relatively high concentrations (1 and 10 µM). At supramicromolar concentrations, dexamethasone binds to and activates PXR producing induction of CYPs such as CYP3A4 (Pascussi et al., 2001 ).
CYP enzyme activities and mRNA levels were determined in primary human hepatocytes The 48-hr treatment resulted in an about 2 or 2.5-fold increase similar to dexamethasone.
Similar effects were observed at the level of CYP2B6 mRNA (Figure 2c ).
PXR activation by DHEA. DHEA is known to induce expression of CYP4As through activation of PPARα. It is also an activator of PXR that mediates induction of CYP3A23 expression in rats (Ripp et al., 2002) . It has been demonstrated that PXR is involved in regulation of the expression of several CYPs (CYP2B6, CYP2C9, CYP2C19 and CYP3A4) in human (Pascussi et al., 2001; Pascussi et al., 2003b) . Our results in human hepatocytes also suggested that DHEA transcriptionally activated CYP genes involving the action of PXR. To 
Discussion
DHEA administration to rats affects the expression of several CYP genes. DHEA has been shown to increase the levels of CYP4As (Prough et al., 1994) and CYP3A23 (Singleton et al., 1999) , and to suppress the expression of CYP2C11 (Ripp et al., 2003) . Nuclear receptors such as PPARα and PXR appear to be involved in DHEA action in rats (Peters et al, 1996; Ripp et al., 2002) . Additionally, 7-oxidized metabolites of DHEA also induce CYP4A1 message and protein levels in rat hepatocytes contributing to the effect of the parent compound (Webb et al., 2006) . In the present study, we therefore investigated the induction of CYPs by DHEA and two of its oxidative metabolites in primary cultures of human hepatocytes and in particular the role of nuclear receptors PXR and CAR in DHEA action.
Human hepatocytes in culture as induction system were validated by testing the classical inducer compound, the steroid dexamethasone on CYP gene expression.
Concentrations of dexamethasone equal or above 1 µM potently increased both the activities and mRNA levels of CYP3A4 and to a lesser extent of CYP2C9, CYP2C19 and CYP2B6.
The present study then revealed that DHEA treatment also elevated the expression and activities of CYP3A4, CYP2C9, CYP2C19 and CYP2B6 similarly to dexamethasone.
Additionally, the DHEA-metabolites 7α-hydroxy-DHEA or 7-oxo-DHEA resulted in the same inducing action as did the parent compound. This means that biotransformation does not lead to inactivation of DHEA as CYP inducer.
The finding that DHEA potently induced CYP3A4 in human hepatocytes was consistent with previous studies in rats (Singleton et al., 1999) . PXR activation has been proposed to mediate the increase in CYP3A expression (Ripp et al., 2002) . But in contrast to studies in rats (Ripp et al., 2003) , DHEA did not mediate suppression of CYP2Cs in human hepatocytes. Moreover, DHEA treatment led to upregulation of both CYP2C9 and CYP2C19
suggesting the involvement of PXR. DHEA was able to activate hPXR in a concentration CAR translocation to the nucleus is the limiting step in the CAR activation process followed by CAR/RXR heterodimer formation and binding of the proteins to the DNA of target genes (Waxman, 1999) . The activation of CAR by DHEA was thus demonstrated in in vitro nuclear translocation assays. Using primary cultures of mouse hepatocytes expressing hCAR, the effect of DHEA on cytoplasmic/nuclear shuttling of CAR was compared to that of CITCO. In agreement with Maglich et al. (2003) , the occurrence of translocation of hCAR from cytoplasm into the nucleus following CITCO treatment was well recognized. DHEA treatment also induced CAR translocation into the nucleus presenting further evidence for CAR activation by DHEA. These findings suggested that CAR was required for maximal induction of Cyp2b10 by DHEA. However, in the absence of CAR, there still is an apparent receptor-mediated induction of CYP mRNA, protein and activity, that could be due to PXR (Ripp et al., 2003) or yet unidentified transcription factors. Cells were treated for 48 hr with dexamethasone (DXM, 1 and 10 µM), DHEA (50 µM) and its metabolites: 7α-hydroxy-DHEA (OH-DHEA, 50 µM) and 7-oxo-DHEA (oxo-DHEA, 50 µM). CYP activities were determined in microsomes prepared from hepatocytes isolated from 6 donors. Levels of CYP2C9, CYP2C19 and CYP2B6 mRNAs were quantified and normalized to GAPDH as described in Materials and Methods. Statistical analysis of the results obtained in untreated and treated cells indicated significant increase in both the activities and mRNA levels as a consequence of various treatments. Controls for each independent experiment were assigned values of 1 and results of treatments are expressed relative to the controls. Error bars represent standard deviations from the mean of 6 donors. 
